Business Wire

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra ®

Reproxalap Statistically Lower than Xiidra for the Two Endpoints of the Trial: Ocular Discomfort (p=0.002) and Ocular Itching (p=0.01) Results Consistent with Data from Post-Acute Ocular Tolerability ...
Business Wire

Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial

Reproxalap Statistically Superior to Vehicle for Both Primary Endpoints of Ocular Redness (P=0.0004) and Schirmer Test (P=0.0005) Schirmer Test ≥10mm Responder Analysis Multiplicity-Controlled ...
Monthly Prescribing Reference

Reproxalap Improves Ocular Discomfort in Second Dry Eye Chamber Trial

Reproxalap 0.25% was superior to vehicle-control on ocular discomfort symptom score from 80 to 100 minutes after chamber entry. Reproxalap ophthalmic solution 0.25% reached the primary endpoint in a ...
Yahoo Finance

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...